Albiruni Abdul Razak, Sebastian Bauer, Jean‐Yves Blay, Richard Quek, Cristina Suárez, Chia‐Chi Lin, Marie Luise Hütter‐Krönke, Ricardo Cubedo, Stéphane Ferretti, Christophe Meille, Ensar Halilovic, Giorgia Clementi, Maria Santos-Rosa, Nelson Guerreiro, Astrid Jullion, Claire Fabre, Antoîne Italiano,
... HDM201 + ribociclib in this patient population. Citation Format: Albiruni Abdul Razak, Sebastian Bauer, Jean-Yves Blay, Richard ...
Tópico(s): Lung Cancer Research Studies
2018 - American Association for Cancer Research | Cancer Research
Arjun Vasant Balar, Amit Mahipal, Enrique Grande, Víctor M. Villalobos, Sébastien Salas, Taek Won Kang, Se Hyun Kim, Thomas Powles, Frank Tsai, Aung Naing, Albiruni Abdul Razak, Yohann Loriot, Ji Youl Lee, Sang Joon Shin, Rafael Morales‐Barrera, Natasha Angra, Feng Xiao, Shaad E. Abdullah, Michiel S. van der Heijden,
... Hyun Kim, Thomas Powles, Frank Tsai, Aung Naing, Albiruni Razak, Yohann Loriot, Ji Youl Lee, Sang Joon ...
Tópico(s): Urinary and Genital Oncology Studies
2018 - American Association for Cancer Research | Cancer Research
Sandra P. D’Angelo, Dejka M. Araujo, Albiruni R. Abdul Razak, Mark Agulnik, Steven Attia, Jean‐Yves Blay, Irene Carrasco García, John A. Charlson, Edwin Choy, George D. Demetri, Mihaela Druta, Édouard Forcade, Kristen N. Ganjoo, John Glod, Vicki L. Keedy, Axel Le Cesne, David A. Liebner, Víctor Moreno, Seth M. Pollack, Scott M. Schuetze, Gary K. Schwartz, Sandra J. Strauss, William D. Tap, Fiona Thistlethwaite, Claudia Maria Valverde Morales, Michael J. Wagner, Breelyn A. Wilky, Cheryl McAlpine, Laura Hudson, Jean‐Marc Navenot, Tianjiao Wang, Jane P. F. Bai, Stavros Rafail, Ruoxi Wang, Amy Sun, Lilliam Fernandes, Erin Van Winkle, Erica Elefant, Colin Lunt, Elliot Norry, Dennis Williams, Swethajit Biswas, Brian Andrew Van Tine,
Summary Background Afamitresgene autoleucel (afami-cel) showed acceptable safety and promising efficacy in a phase 1 trial (NCT03132922). The aim of this study was to further evaluate the efficacy of afami-cel for the treatment of patients with HLA-A*02 and MAGE-A4-expressing advanced synovial sarcoma or myxoid round cell liposarcoma. Methods SPEARHEAD-1 was an open-label, non-randomised, phase 2 trial done across 23 sites in Canada, the USA, and Europe. The trial included three cohorts, of which the main ...
Tópico(s): Immunotherapy and Immune Responses
2024 - Elsevier BV | The Lancet
Michael C. Heinrich, Robin L. Jones, Suzanne George, Hans Gelderblom, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Yoon‐Koo Kang, Albiruni Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, Brittany L. Siontis, David Goldstein, Kjetil Boye, César Sánchez, Neeltje Steeghs, Piotr Rutkowski, Mihaela Druta, César Serrano, Neeta Somaiah, Ping Chi, William M. Reichmann, Kam Sprott, Haroun Achour, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Jean‐Yves Blay, Sebastian Bauer,
Abstract INTRIGUE was an open-label, phase 3 study in adult patients with advanced gastrointestinal stromal tumor who had disease progression on or intolerance to imatinib and who were randomized to once-daily ripretinib 150 mg or sunitinib 50 mg. In the primary analysis, progression-free survival (PFS) with ripretinib was not superior to sunitinib. In clinical and nonclinical studies, ripretinib and sunitinib have demonstrated differential activity based on the exon location of KIT mutations. Therefore, ...
Tópico(s): Gastric Cancer Management and Outcomes
2024 - Nature Portfolio | Nature Medicine
Hans Gelderblom, Vivek A. Bhadri, Silvia Stacchiotti, Sebastian Bauer, Andrew J. Wagner, Michiel A. J. van de Sande, Nicholas M. Bernthal, Antonio López‐Pousa, Albiruni Abdul Razak, Antoîne Italiano, Mahbubl Ahmed, Axel Le Cesne, Gabriel Tinoco, Kjetil Boye, Javier Martín‐Broto, Emanuela Palmerini, Salvatore Tafuto, Sarah Pratap, Benjamin Powers, Peter Reichardt, Antonio Casado, Piotr Rutkowski, Christopher Tait, Fiona Zarins, B. Harrow, Maitreyi G. Sharma, Rodrigo Ruiz‐Soto, Matthew L. Sherman, Jean‐Yves Blay, William D. Tap, Herbert H. Loong, Antonella Brunello, Andreas H. Krieg, Mark Algulnik, Richard F. Riedel, Scott H. Okuno, Elizabeth T. Loggers, Thierry Alcindor, Virginia Ferraresi, César Serrano, R. Lor Randall, Breelyn A. Wilky, Vinod Ravi,
Background Tenosynovial giant cell tumour (TGCT) is a locally aggressive neoplasm for which few systemic treatment options exist. This study evaluated the efficacy and safety of vimseltinib, an oral, switch-control, CSF1R inhibitor, in patients with symptomatic TGCT not amenable to surgery. Methods MOTION is a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial done in 35 specialised hospitals in 13 countries. Eligible patients were adults (aged ≥18 years) with a histologically ...
Tópico(s): Elbow and Forearm Trauma Treatment
2024 - Elsevier BV | The Lancet
Anthony B. El-Khoueiry, James S. Clarke, Tobias Neff, T. Crossman, Nirav Ratia, Chetan Rathi, Paul Noto, Aarti Tarkar, Ignacio Garrido‐Laguna, Emiliano Calvo, Jordi Rodón, Ben Tran, Peter J. O’Dwyer, Adam Cuker, Albiruni R. Abdul Razak,
GSK3368715, a first-in-class, reversible inhibitor of type I protein methyltransferases (PRMTs) demonstrated anticancer activity in preclinical studies. This Phase 1 study (NCT03666988) evaluated safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of GSK3368715 in adults with advanced-stage solid tumors.In part 1, escalating doses of oral once-daily GSK3368715 (50, 100, and 200 mg) were evaluated. Enrollment was paused at 200 mg following a higher-than-expected incidence of thromboembolic ...
Tópico(s): Epigenetics and DNA Methylation
2023 - Springer Nature | British Journal of Cancer
Anas Gazzah, Philippe L. Bédard, Cinta Hierro, Yubin Kang, Albiruni Abdul Razak, M.H. Ryu, B. Demers, Nathalie Fagniez, Christophe Henry, Marie Hospitel, J.C. Soria, Josep Tabernero,
Tusamitamab ravtansine (SAR408701) is an antibody-drug conjugate composed of a humanized monoclonal antibody that binds carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5) and a cytotoxic maytansinoid that selectively targets CEACAM5-expressing tumor cells. In this phase I dose-escalation study, we evaluated the safety, pharmacokinetics, and preliminary antitumor activity of tusamitamab ravtansine in patients with solid tumors.Eligible patients were aged ≥18 years, had locally advanced/ ...
Tópico(s): Radiopharmaceutical Chemistry and Applications
2022 - Elsevier BV | Annals of Oncology
Michael C. Heinrich, Robin L. Jones, Hans Gelderblom, Suzanne George, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Yoon‐Koo Kang, Albiruni Ryan Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, Ying Su, Julie Nicole Meade, Tao Wang, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Jean‐Yves Blay, Sebastian Bauer,
359881 Background: Sunitinib is approved for advanced gastrointestinal stromal tumor (GIST) after imatinib failure. Ripretinib, a broad-spectrum KIT and PDGFRA switch-control tyrosine kinase inhibitor (TKI), is indicated for the treatment of adult patients (pts) with GIST who received prior treatment with 3 or more TKIs, including imatinib. We compared the efficacy and safety of ripretinib vs sunitinib in pts with advanced GIST who progressed on or were intolerant to imatinib. Methods: This multicenter, ...
Tópico(s): Gastric Cancer Management and Outcomes
2022 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Silvia Stacchiotti, Anna Maria Frezza, George D. Demetri, Jean‐Yves Blay, Jyoti Bajpai, Giacomo Giulio Baldi, Elizabeth H. Baldini, Robert S. Benjamin, Sylvie Bonvalot, Judith V.M.G. Bovée, Dario Callegaro, Paolo G. Casali, Sandra P. D’Angelo, Elizabeth J. Davis, Angelo Paolo Dei Tos, Elizabeth G. Demicco, Jayesh Desai, Palma Dileo, Mikael Eriksson, Hans Gelderblom, Suzanne George, Rebecca Gladdy, Mrinal M. Gounder, Abha A. Gupta, Rick L. M. Haas, Andrea Giráldez Hayes, Peter Hohenberger, Kevin B. Jones, Robin L. Jones, Bernd Kasper, Akira Kawai, David G. Kirsch, Eugenie S. Kleinerman, Axel Le Cesne, Roberta Maestro, Javier Martín‐Broto, Robert G. Maki, Aisha Miah, Emanuela Palmerini, Shreaskumar R. Patel, Chandrajit P. Raut, Albiruni R. Abdul Razak, Damon R. Reed, Piotr Rutkowski, Roberta Sanfilippo, Marta Sbaraglia, Inga‐Marie Schaefer, D. Strauß, Sandra J. Strauss, William D. Tap, David M. Thomas, Annalisa Trama, Jonathan C. Trent, Winette T.A. van der Graaf, Winan J. van Houdt, Margaret von Mehren, Breelyn A. Wilky, Christopher D.�M. Fletcher, Alessandro Gronchi, Rosalba Miceli, Andrew J. Wagner,
BackgroundIn ultra-rare sarcomas (URS) the conduction of prospective, randomized trials is challenging. Data from retrospective observational studies (ROS) may represent the best evidence available. ROS implicit limitations led to poor acceptance by the scientific community and regulatory authorities. In this context, an expert panel from the Connective Tissue Oncology Society (CTOS), agreed on the need to establish a set of minimum requirements for conducting high-quality ROS on the activity of systemic ...
Tópico(s): Cardiac tumors and thrombi
2022 - Elsevier BV | Cancer Treatment Reviews
Giuseppe Curigliano, Geoffrey I. Shapiro, Rebecca Kristeleit, Albiruni R. Abdul Razak, Stephen Leong, María Alsina, Antonio Giordano, Karen A. Gelmon, Erica Stringer-Reasor, Ulka N. Vaishampayan, Mark R. Middleton, Anthony J. Olszanski, Hope S. Rugo, Kenneth A. Kern, Nazima Pathan, Rachelle Perea, Kristen J. Pierce, Sarah C. Mutka, Zev A. Wainberg,
This Phase 1b study (B2151002) evaluated the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with other anti-tumour agents in advanced solid tumours.Patients with various malignancies were administered gedatolisib (90‒310 mg intravenously every week [QW]) plus docetaxel (arm A) or cisplatin (arm B) (each 75 mg/m2 intravenously Q3W) or dacomitinib (30 or 45 mg/day orally). The safety and tolerability of combination therapies were assessed during dose escalation; objective response (OR) and safety ...
Tópico(s): HER2/EGFR in Cancer Research
2022 - Springer Nature | British Journal of Cancer
Nicolás Devaud, Olga Vornicova, Albiruni R. Abdul Razak, Korosh Khalili, Elizabeth G. Demicco, Cristina Mitric, Marcus Q. Bernardini, Rebecca Gladdy,
Leiomyosarcomas are soft tissue tumors that are derived from smooth muscle mainly in the pelvis and retroperitoneum. Percutaneous biopsy is paramount to confirm diagnosis. Imaging is necessary to complete clinical staging. Multimodal treatment should be directed by expert sarcoma multidisciplinary teams that see a critical volume of these rare tumors. Surgery is the mainstay of curative intent treatment; however due to its high metastatic progression, there may be a benefit for neoadjuvant systemic ...
Tópico(s): Vascular Tumors and Angiosarcomas
2022 - Elsevier BV | Surgical Oncology Clinics of North America
Sebastian Bauer, Robin L. Jones, Jean‐Yves Blay, Hans Gelderblom, Suzanne George, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Yoon‐Koo Kang, Albiruni Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, Ying Su, Julie Meade, Tao Wang, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Michael C. Heinrich,
PURPOSE Sunitinib, a multitargeted tyrosine kinase inhibitor (TKI), is approved for advanced gastrointestinal stromal tumor (GIST) after imatinib failure. Ripretinib is a switch-control TKI approved for advanced GIST after prior treatment with three or more TKIs, including imatinib. We compared efficacy and safety of ripretinib versus sunitinib in patients with advanced GIST who were previously treated with imatinib (INTRIGUE, ClinicalTrials.gov identifier: NCT03673501 ). PATIENTS AND METHODS Random assignment ...
Tópico(s): Gastrointestinal disorders and treatments
2022 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Mrinal M. Gounder, Albiruni Abdul Razak, Neeta Somaiah, Sant P. Chawla, Javier Martín‐Broto, Giovanni Grignani, Scott M. Schuetze, Bruno Vincenzi, Andrew J. Wagner, Bartosz Chmielowski, Robin L. Jones, Richard F. Riedel, Silvia Stacchiotti, Elizabeth T. Loggers, Kristen N. Ganjoo, Axel Le Cesne, Antoîne Italiano, Xavier García del Muro, Melissa Burgess, Sophie Piperno‐Neumann, Christopher W. Ryan, Mary F. Mulcahy, Charles Forscher, Nicolas Penel, Scott H. Okuno, Anthony Elias, Lee Hartner, Tony Philip, Thierry Alcindor, Bernd Kasper, Peter Reichardt, Lore Lapeire, Jean‐Yves Blay, Christine Chevreau, Claudia Maria Valverde Morales, Gary K. Schwartz, James L. Chen, Hari A. Deshpande, Elizabeth J. Davis, Garth Nicholas, Stefan Gröschel, Helen Hatcher, Florence Duffaud, Antonio Casado, Roberto Díaz Beveridge, Giuseppe Badalamenti, Mikael Eriksson, Christian F. Meyer, Margaret von Mehren, Brian A. Van Tine, Katharina S. Götze, F Mazzeo, Alexander Yakobson, Aviad Zick, Alexander T.J. Lee, Anna Estival, Andrea Napolitano, Mark A. Dickson, Dayana Michel, Changting Meng, Lingling Li, Jianjun Liu, Osnat Ben‐Shahar, Dane R. Van Domelen, Christopher J. Walker, Hua Chang, Yosef Landesman, Jatin J. Shah, Sharon Shacham, Michael Kauffman, Steven Attia,
Antitumor activity in preclinical models and a phase I study of patients with dedifferentiated liposarcoma (DD-LPS) was observed with selinexor. We evaluated the clinical benefit of selinexor in patients with previously treated DD-LPS whose sarcoma progressed on approved agents.
Tópico(s): Cardiac tumors and thrombi
2022 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Anthony W. Tolcher, Benedito A. Carneiro, Afshin Dowlati, Albiruni Ryan Abdul Razak, Young Kwang Chae, Jeannine Villella, Sheryl Coppola, Stefan Englert, Andrew C. Phillips, Andrew J. Souers, Zeena Salman, Sudhir Penugonda, John D. Powderly, Patricia LoRusso,
3015 Background: Mirzotamab clezutoclax (ABBV-155) is a first-in-class antibody drug conjugate comprised of a BCL-X L (B-cell lymphoma - extra long) inhibitor, solubilizing linker, and a monoclonal anti-B7H3 antibody. Methods: Patients (pts) with relapsed and/or refractory (R/R) solid tumors were administered mirzotamab clezutoclax with or without paclitaxel. Dose escalation of mirzotamab clezutoclax was guided by Bayesian continual reassessment. Primary outcomes were to determine the maximum tolerated ...
Tópico(s): Lung Cancer Treatments and Mutations
2021 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Justin Bader, Albiruni Ryan Abdul Razak, Sharon Shacham, Hongmei Xu,
Tópico(s): Cancer-related Molecular Pathways
2021 - Adis, Springer Healthcare | Clinical Pharmacokinetics
Nathaniel D. Anderson, Yael Babichev, Fabio Fuligni, Federico Comitani, Mehdi Layeghifard, Rosemarie E. Venier, Stefan C. Dentro, Anant Maheshwari, Sheena Guram, Claire Wunker, John Thompson, Kyoko E. Yuki, Huayun Hou, Matthew Zatzman, Nicholas Light, Marcus Q. Bernardini, Jay S. Wunder, Irene L. Andrulis, Peter C. Ferguson, Albiruni R. Abdul Razak, Carol J. Swallow, James J. Dowling, Rima Al‐awar, Richard Marcellus, Marjan Rouzbahman, Moritz Gerstung, Daniel Durocher, Ludmil B. Alexandrov, Brendan C. Dickson, Rebecca Gladdy, Adam Shlien,
Leiomyosarcomas (LMS) are genetically heterogeneous tumors differentiating along smooth muscle lines. Currently, LMS treatment is not informed by molecular subtyping and is associated with highly variable survival. While disease site continues to dictate clinical management, the contribution of genetic factors to LMS subtype, origins, and timing are unknown. Here we analyze 70 genomes and 130 transcriptomes of LMS, including multiple tumor regions and paired metastases. Molecular profiling highlight ...
Tópico(s): Lymphoma Diagnosis and Treatment
2021 - Nature Portfolio | Nature Communications
Albiruni R. Abdul Razak, Sebastian Bauer, Cristina Suárez, Chia‐Chi Lin, Richard Quek, Marie Luise Hütter‐Krönke, Ricardo Cubedo, Stéphane Ferretti, Nelson Guerreiro, Astrid Jullion, Elena J. Orlando, Giorgia Clementi, Janna Dejmek, Ensar Halilovic, Claire Fabre, Jean‐Yves Blay, Antoîne Italiano,
Abstract Purpose: Well-differentiated (WDLPS) and dedifferentiated (DDLPS) liposarcoma are characterized by co-amplification of the murine double minute-2 (MDM2) and cyclin-dependent kinase-4 (CDK4) oncogenes. Siremadlin, a p53–MDM2 inhibitor, was combined with ribociclib, a CDK4/6 inhibitor, in patients with locally advanced/metastatic WDLPS or DDLPS who had radiologically progressed on, or despite, prior systemic therapy. Patients and Methods: In this proof-of-concept, phase Ib, dose-escalation study, ...
Tópico(s): Multiple Myeloma Research and Treatments
2021 - American Association for Cancer Research | Clinical Cancer Research
Anna Spreafico, Aaron R. Hansen, Albiruni R. Abdul Razak, Philippe L. Bédard, Lillian L. Siu,
Abstract Clinical trials represent a fulcrum for oncology drug discovery and development to bring safe and effective medicines to patients in a timely manner. Clinical trials have shifted from traditional studies evaluating cytotoxic chemotherapy in largely histology-based populations to become adaptively designed and biomarker-driven evaluations of molecularly targeted agents and immune therapies in selected patient subsets. This review will discuss the scientific, methodological, practical, and ...
Tópico(s): Radiomics and Machine Learning in Medical Imaging
2021 - American Association for Cancer Research | Cancer Discovery
S.Y. Cindy Yang, Scott Lien, Ben X. Wang, Derek Clouthier, Youstina Hanna, Iulia Cirlan, Kelsey Zhu, Jeffrey P. Bruce, Samah El Ghamrasni, Marco Iafolla, Marc Oliva, Aaron R. Hansen, Anna Spreafico, Philippe L. Bédard, Stéphanie Lheureux, Albiruni Abdul Razak, Vanessa Speers, Hal K. Berman, Alexey Aleshin, Benjamin Haibe‐Kains, David G. Brooks, Tracy L. McGaha, Marcus O. Butler, Scott V. Bratman, Pamela S. Ohashi, Lillian L. Siu, Trevor J. Pugh,
Abstract Serial circulating tumor DNA (ctDNA) monitoring is emerging as a non-invasive strategy to predict and monitor immune checkpoint blockade (ICB) therapeutic efficacy across cancer types. Yet, limited data exist to show the relationship between ctDNA dynamics and tumor genome and immune microenvironment in patients receiving ICB. Here, we present an in-depth analysis of clinical, whole-exome, transcriptome, and ctDNA profiles of 73 patients with advanced solid tumors, across 30 cancer types, ...
Tópico(s): Ferroptosis and cancer prognosis
2021 - Nature Portfolio | Nature Communications
Silvia Stacchiotti, Anna Maria Frezza, Jean‐Yves Blay, Elizabeth H. Baldini, Sylvie Bonvalot, Judith V.M.G. Bovée, Dario Callegaro, Paolo G. Casali, RuRu Chun-Ju Chiang, George D. Demetri, Elisabeth G. Demicco, Jayesh Desai, Mikael Eriksson, Hans Gelderblom, Suzanne George, Mrinal M. Gounder, Alessandro Gronchi, Abha A. Gupta, Rick L. Haas, Andrea Hayes‐Jardon, Peter Hohenberger, Kevin B. Jones, Robin L. Jones, Bernd Kasper, Akira Kawai, David G. Kirsch, Eugene S. Kleinerman, Axel Le Cesne, Jiwon Lim, María Dolores Chirlaque López, Roberta Maestro, Rafael Marcos‐Gragera, Javier Martín‐Broto, Tomohiro Matsuda, Olivier Mir, Shreyaskumar Patel, Chandrajit P. Raut, Albiruni R. Abdul Razak, Damon R. Reed, Piotr Rutkowski, Roberta Sanfilippo, Marta Sbaraglia, Inga‐Marie Schaefer, D. Strauß, Kirsten Sundby Hall, William D. Tap, David M. Thomas, Winette T.A. van der Graaf, Winan J. van Houdt, Otto Visser, Margaret von Mehren, Andrew J. Wagner, Breelyn A. Wilky, Young‐Joo Won, Christopher D.�M. Fletcher, Angelo Paolo Dei Tos, Annalisa Trama,
Background Among sarcomas, which are rare cancers, many types are exceedingly rare; however, a definition of ultra‐rare cancers has not been established. The problem of ultra‐rare sarcomas is particularly relevant because they represent unique diseases, and their rarity poses major challenges for diagnosis, understanding disease biology, generating clinical evidence to support new drug development, and achieving formal authorization for novel therapies. Methods The Connective Tissue Oncology Society ...
Tópico(s): Bone Tumor Diagnosis and Treatments
2021 - Wiley | Cancer
Zachary Veitch, Daniel Shepshelovich, Christina Gallagher, Lisa Wang, Albiruni R. Abdul Razak, Anna Spreafico, Philippe L. Bédard, Lillian L. Siu, Lori M. Minasian, Aaron R. Hansen,
Abstract Background Clinician reporting of symptomatic adverse events (AEs) in phase I trials uses the Common Terminology Criteria for Adverse Events (CTCAE). The utility of the patient-reported outcomes (PROs) version of the CTCAE (PRO-CTCAE) in this setting is unknown. This prospective, observational study compared patient- and clinician-reported symptomatic AEs in phase I patients. Methods Phase I study–eligible patients at Princess Margaret were surveyed with the PRO-CTCAE full-item library (78 symptomatic ...
Tópico(s): Cancer survivorship and care
2021 - Oxford University Press | JNCI Journal of the National Cancer Institute
Silvia Stacchiotti, Aisha Miah, Anna Maria Frezza, Christina Messiou, Carlo Morosi, Augusto Caraceni, Cristina R. Antonescu, Jyoti Bajpai, Elizabeth H. Baldini, Sebastian Bauer, R. Biagini, Stefan Bielack, Jean‐Yves Blay, Sylvie Bonvalot, I. Boukovinas, Judith V.M.G. Bovée, Kjetil Boye, Thomas Brodowicz, Dario Callegaro, Enrique de Álava, M. Deoras-Sutliff, Armelle Dufresne, Mikael Eriksson, Costantino Errani, А. А. Феденко, Virginia Ferraresi, Andrea Ferrari, Christopher D.�M. Fletcher, Xavier García del Muro, Hans Gelderblom, Rebecca Gladdy, F. Gouin, Giovanni Grignani, J. Gutkovich, Rick L. Haas, Nadia Hindi, Peter Hohenberger, Paul H. Huang, Heikki Joensuu, Robin L. Jones, Christiane Jungels, Bernd Kasper, Akira Kawai, Axel Le Cesne, Franel le Grange, Andreas Leithner, Hugh Leonard, Antonio López‐Pousa, Javier Martín‐Broto, Ofer Merimsky, Priscilla Merriam, Rosalba Miceli, Olivier Mir, Michele Molinari, Michael Montemurro, Graziano Oldani, Emanuela Palmerini, Maria A. Pantaleo, S. Patel, Sophie Piperno‐Neumann, Chandrajit P. Raut, Vinod Ravi, Albiruni R. Abdul Razak, Peter Reichardt, Brian P. Rubin, Piotr Rutkowski, Akmal Safwat, Claudia Sangalli, Gonzalo Sapisochín, Marta Sbaraglia, S. Scheipl, Patrick Schöffski, D. Strauß, Sandra J. Strauss, Kirsten Sundby Hall, William D. Tap, Annalisa Trama, Andrew Tweddle, Winette T.A. van der Graaf, Michiel A. J. van de Sande, Winan J. van Houdt, G. van Oortmerssen, Andrew J. Wagner, Markus Wartenberg, Jayne Wood, Nadia Zaffaroni, Camilla Zimmermann, Paolo G. Casali, Angelo Paolo Dei Tos, Alessandro Gronchi,
•This consensus paper provides key recommendations on the management of epithelioid hemangioendothelioma (EHE).•Recommendations followed a consensus meeting between experts and a representative of the EHE advocacy group and SPAEN.•Authorship includes a multidisciplinary group of experts from different institutions from Europe, North America and Asia. Epithelioid hemangioendothelioma (EHE) is an ultra-rare, translocated, vascular sarcoma. EHE clinical behavior is variable, ranging from that of a low- ...
Tópico(s): Cardiac tumors and thrombi
2021 - Elsevier BV | ESMO Open
Sandra P. D’Angelo, Brian Andrew Van Tine, Steven Attia, Jean‐Yves Blay, Sandra J. Strauss, Claudia Maria Valverde Morales, Albiruni Ryan Abdul Razak, Erin Van Winkle, Trupti Trivedi, Swethajit Biswas, Dennis Williams, Elliot Norry, Dejka M. Araujo,
11504 Background: This phase 2, open-label trial (SPEARHEAD-1; NCT04044768) is designed to evaluate the efficacy, safety, and tolerability of afamitresgene autoleucel in 45 patients (pts) with advanced/metastatic synovial sarcoma or Myxoid/Round Cell Liposarcoma (MRCLS). Methods: Eligible pts are HLA-A*02 positive with MAGE-A4-expressing tumors. Pts undergo leukapheresis for collection of autologous T-cells for processing and manufacture into afamitresgene autoleucel cells. Pts were treated with afamitresgene ...
Tópico(s): Immunotherapy and Immune Responses
2021 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Suzanne George, Ping Chi, Michael C. Heinrich, Margaret von Mehren, Robin L. Jones, Kristen N. Ganjoo, Jonathan C. Trent, Hans Gelderblom, Albiruni Abdul Razak, Michael S. Gordon, Neeta Somaiah, Julia Jennings, Julie Meade, Kelvin Shi, Ying Su, Rodrigo Ruiz‐Soto, Filip Janků,
Abstract Purpose Ripretinib is a switch-control tyrosine kinase inhibitor that broadly inhibits KIT and platelet-derived growth factor receptor α kinase signalling. Ripretinib showed preliminary efficacy in patients with advanced gastrointestinal stromal tumour (GIST) in a phase I study across a range of doses. Results were confirmed in the phase III INVICTUS study, and ripretinib 150 mg once daily (QD) was subsequently approved as a ≥fourth-line therapy. Here, we report the phase I study results of intrapatient ...
Tópico(s): Gastric Cancer Management and Outcomes
2021 - Elsevier BV | European Journal of Cancer
William D. Tap, Andrew J. Wagner, Patrick Schöffski, Javier Martín‐Broto, Anders Krarup‐Hansen, Kristen N. Ganjoo, Chueh‐Chuan Yen, Albiruni R. Abdul Razak, Alexander I. Spira, Akira Kawai, Axel Le Cesne, Brian A. Van Tine, Yoichi Naito, Se Hoon Park, А. А. Феденко, Zsuzsanna Pápai, Victoria Soldatenkova, Ashwin Shahir, Gary Mo, Jennifer Wright, Robin L. Jones,
Patients with advanced soft tissue sarcoma (STS) have a median overall survival of less than 2 years. In a phase 2 study, an overall survival benefit in this population was observed with the addition of olaratumab to doxorubicin over doxorubicin alone.To determine the efficacy of doxorubicin plus olaratumab in patients with advanced/metastatic STS.ANNOUNCE was a confirmatory, phase 3, double-blind, randomized trial conducted at 110 sites in 25 countries from September 2015 to December 2018; the final ...
Tópico(s): Neurofibromatosis and Schwannoma Cases
2020 - American Medical Association | JAMA
Albiruni RA Razak, James M. Cleary, Víctor Moreno, Michael Boyer, Emiliano Calvo, William J. Edenfield, Jeanne Tie, R. Donald Harvey, Annemie Rutten, Manish A. Shah, Anthony J. Olszanski, Dirk Jäger, Nehal J. Lakhani, David P. Ryan, Erik Rasmussen, Gloria Juan, Hansen Wong, Neelesh Soman, Marie-Anne Damiette Smit, Dirk Nagorsen, Kyriakos P. Papadopoulos,
To determine the safety and efficacy of the anti-colony-stimulating factor 1 receptor (anti-CSF1R) monoclonal antibody AMG 820 in combination with pembrolizumab in patients with select solid tumors.Patients had advanced, refractory mismatch repair-proficient colorectal cancer, pancreatic cancer, or non-small cell lung cancer (NSCLC) with low (<50%) programmed cell death-ligand 1 (PD-L1) expression and were naïve to anti-programmed cell death-1 (PD-1)/PD-L1 or had relapsed/refractory NSCLC after anti-PD- ...
Tópico(s): Cancer, Stress, Anesthesia, and Immune Response
2020 - BMJ | Journal for ImmunoTherapy of Cancer
Filip Janků, Albiruni R. Abdul Razak, Ping Chi, Michael C. Heinrich, Margaret von Mehren, Robin L. Jones, Kristen N. Ganjoo, Jonathan C. Trent, Hans Gelderblom, Neeta Somaiah, Simin Hu, Oliver Rosen, Ying Su, Rodrigo Ruiz‐Soto, Michael S. Gordon, Suzanne George,
In advanced gastrointestinal stromal tumor (GIST), there is an unmet need for therapies that target both primary and secondary mutations of pathogenic KIT/PDGFRA oncoproteins. Ripretinib is a novel switch-control kinase inhibitor designed to inhibit a wide range of
Tópico(s): Neurofibromatosis and Schwannoma Cases
2020 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Marco Iafolla, Cindy Yang, Vinod Chandran, Melania Pintilie, Quan Li, Philippe L. Bédard, Aaron R. Hansen, Stéphanie Lheureux, Anna Spreafico, Albiruni Abdul Razak, Sevan Hakgor, Amanda Giesler, Trevor J. Pugh, Lillian L. Siu,
Abstract Background Human leukocyte antigen class 1 (HLA-1)–dependent immune activity is linked to autoimmune diseases. HLA-1–dependent CD8+ T cells are required for immune checkpoint blockade antitumor activity. It is unknown if HLA-1 genotype is predictive of toxicity to immune checkpoint blockade. Methods Patients with advanced solid tumors stratified into 5 cohorts received single agent pembrolizumab (anti-programmed cell death-1) 200 mg intravenously every 3 weeks in an investigator-initiated ...
Tópico(s): T-cell and B-cell Immunology
2020 - Oxford University Press | JNCI Cancer Spectrum
María Vieito, Anna Spreafico, Víctor Moreno, Irene Braña, Tatiana Hernández, Albiruni Abdul Razak, J. Wang, Nahor Haddish‐Berhane, Jaydeep Mehta, Amy J. Johnson, Anke Maes, John L. Haslam, Pankaj Mistry, Anna Kalota, Laurie Lenox, Jon Infante, Matthew V. Lorenzi, Hong Xie, Josh Lauring, Manish R. Patel,
PRMT5 regulates proteins important for tumorigenesis via symmetric arginine dimethylation (SDMA). JNJ64619178 is an oral, potent and selective PRMT5 inhibitor that demonstrates efficacy in multiple tumor models. Here, we present a phase I study of JNJ64619178 in adults with advanced solid tumors and non-Hodgkin lymphoma (Part 1). Dose escalation was supported by a modified continual reassessment method. Patients (pts) received JNJ64619178 either intermittently (14 days on/7 days off) or once daily (QD) ...
Tópico(s): Cancer-related gene regulation
2020 - Elsevier BV | Annals of Oncology
Scott V. Bratman, S.Y. Cindy Yang, Marco Iafolla, Zhihui Liu, Aaron R. Hansen, Philippe L. Bédard, Stéphanie Lheureux, Anna Spreafico, Albiruni Abdul Razak, Svetlana Shchegrova, Maggie C. Louie, Paul R. Billings, Bernhard Zimmermann, Himanshu Sethi, Alexey Aleshin, Dax Torti, Kayla Marsh, Jenna Eagles, Iulia Cirlan, Youstina Hanna, Derek Clouthier, Scott Lien, Pamela S. Ohashi, Wei Xu, Lillian L. Siu, Trevor J. Pugh,
Tópico(s): Lung Cancer Treatments and Mutations
2020 - Nature Portfolio | Nature Cancer